Achillion Pharmaceuticals has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in an ongoing Phase 1 clinical trial. Furthermore, the company said that the FDA has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV … more

Investor interest in Achillion is high following recent developments … more